-
Posted by
Two Blokes Jul 2 -
Filed in
Stock
-
6 views
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceeds of $50 million. The clincial study, in partnership with Beckley Psytech, is evaluating BPL-003, a formulation of the psychedelic compound mebufotenin, also known as DMT, that is administered using a nasal spray.
